Source link : https://www.newshealth.biz/health-news/worse-pfs-seen-with-nivolumab-rucaparib-in-ovarian-cancer/
The addition of nivolumab to rucaparib did not lead to better progression-free survival than rucaparib monotherapy in patients with newly diagnosed, advanced, high-grade ovarian cancer (AHGOC), a new study has found. Bradley J. Monk, MD, presented this finding and other results of the ATHENA-COMBO study, at the European Society for Medical Oncology Congress 2024. The […]
Author : News Health
Publish date : 2024-09-15 21:14:49
Copyright for syndicated content belongs to the linked Source.